Defendant Name: Alexion Pharmaceuticals, Inc.

Defendant Type: Public Company
SIC Code: 2830
CUSIP: 01535110

Initial Case Details

Legal Case Name In the Matter of Alexion Pharmaceuticals, Inc.
First Document Date 02-Jul-2020
Initial Filing Format Administrative Action
File Number 3-19852
Allegation Type Foreign Corrupt Practices Act
AAER 4151

Violations Alleged

Exchange Act
Sec 13(b)(2)(A)
Sec 13(b)(2)(B)


First Resolution Date 02-Jul-2020
Headline Total Penalty and Disgorgement

See Related Documents

Related Documents:

34-89214 02-Jul-2020 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order
On July 2, 2020, the SEC instituted settled cease-and-desist proceedings against Alexion Pharmaceuticals, Inc. The SEC stated: "These proceedings arise out of Alexion's violations of the internal accounting controls and recordkeeping provisions of the Foreign Corrupt Practices Act of 1977."
2020-149 02-Jul-2020 Press Release--Administrative Proceeding
SEC Charges Alexion Pharmaceuticals with FCPA Violations
The SEC stated that: "Boston-based pharmaceutical company Alexion Pharmaceuticals Inc. has agreed to pay more than $21 million to resolve charges that it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act (FCPA)."